Bonlutin

Australia - English - Department of Health (Therapeutic Goods Administration)

Buy It Now

Active ingredient:
glucosamine sulfate potassium chloride,natural fish oil,shark sodium chondroitin sulfate
Available from:
Pharmametics Products A Division of Max Biocare Pty Ltd
Authorization status:
Listed
Authorization number:
321277

Public Summary

Summary for ARTG Entry:

321277

Bonlutin

ARTG entry for

Medicine Listed

Sponsor

Pharmametics Products A Division of Max Biocare Pty Ltd

Postal Address

Level 1-2 667 Chapel Street,South Yarra, VIC, 3141

Australia

ARTG Start Date

5/08/2019

Product category

Medicine

Status

Active

Approval area

Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in

the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine,

(b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is

sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be

kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records

to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted

in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office

of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors

of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified

of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine

outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National

Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1. Bonlutin

Product Type

Single Medicine Product

Effective date

5/08/2019

Permitted Indications

Antioxidant/Reduce free radicals formed in the body

Anti-inflammatory/relieve inflammation

Decrease/reduce/relieve mild joint aches and pains

Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis

Helps maintain/supports health joint cartilage growth/development/production

Helps enhance/promote healthy joint function

Helps enhance/promote joint health

Maintain/support joint health

Decrease/reduce/relieve mild joint inflammation/swelling

Maintain/support joint mobility/flexibility

Decrease/reduce/relieve mild joint pain/soreness

Decrease/reduce/relieve mild joint stiffness

Indication Requirements

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis,

osteoporosis.

Product presentation must only refer to mild joint symptoms.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to any form of arthritis or osteoarthritis unless qualified as mild.

Standard Indications

Public Summary

Page 1 of

Produced at 29.08.2019 at 05:33:14 AEST

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

No Standard Indications included on Record

Specific Indications

Warnings

Contains potassium. If you have kidney disease or are taking heart or blood pressure medicines, consult your doctor or pharmacist before use. Keep out

of reach of children.

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1. Formulation 1

Dosage Form

Capsule, soft

Route of Administration

Oral

Visual Identification

Active Ingredients

glucosamine sulfate potassium chloride

500 mg

natural fish oil

600 mg

shark sodium chondroitin sulfate

12.33 mg

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 2 of

Produced at 29.08.2019 at 05:33:14 AEST

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

Similar products

Search alerts related to this product

Share this information